The rebranding of the firm is subject to approval of the Registrar of companies in India.
Mylan expects to keep the Matrix name for the institutional ARV franchise, serving NGOs and other alliances.
Mylan chairman and CEO Robert Coury said this rebranding will lay the groundwork for continued expansion in India through their entry into the Indian commercial market with their own prescription pharmaceuticals within the next 12 months.
"In order to support the commercial launch and other growth opportunities in India, we expect to continue to expand our workforce over the coming years and aim to attract the caliber talent both from within India and internationally," Coury said.